Como se combate o populismo? "Com eleições", responde Fukuyama

[novo_nisto]

Não me lembro exactamente mas penso que a resistência dos 35USD já foi testada mais vezes sim. Penso que pode subir porque a razão que a fez cair não tem impacto no futuro dos resultados da empresa, terá sido panic sell.

Deixo a razão da queda:


CHICAGO, June 28 (Reuters) - Biomet Inc. (BMET.O: Quote, Profile, Research), the orthopedic device maker that recently said it could put itself on the block, on Wednesday said quarterly net profit fell 5 percent on one-time charges including a severance package for its former chief executive.

Fiscal fourth-quarter net income fell to $98.5 million, or 40 cents a share, from $103.2 million, or 41 cents a share, a year ago.


Adjusted earnings rose 8 percent to $113.0 million, or 46 cents per share, from $104.8 million, or 42 cents a share, a year ago.

Wall Street on average had expected Warsaw, Indiana-based Biomet to earn 46 cents a share, according to Reuters Estimates.

Analysts said the quarter was mostly in line with lowered expectations after Biomet posted disappointing results through much of fiscal 2006.

Its shares, which have come under pressure along with orthopedic stocks from slowing growth in hip and knee demand and recently issued government subpoenas, rose 3.7 percent to $32.35 in premarket activity on INET.

Net sales increased 7 percent to $539.9 million. Sales of knee implants, up 15 percent worldwide, exceeded forecasts. Hip sales rose 10 percent.

"The better than expected sales growth for BMET's (reconstructive implants) is a plus," Merrill Lynch analyst Katherine Martinelli wrote in a note.

Biomet took one-time charges that included a $9 million severance package for company founder Dane Miller, $5.4 million in expenses related to the reorganization of its EBI operations and $4.8 million for the discontinuation of the Acumen surgical navigation product line.

The company said it remained comfortable with analysts' sales estimates in the first quarter of $513 million to $530 million, and earnings estimates of 43 cents to 45 cents per share.

Biomet said the earnings estimates did not include the effect of an accounting rule for expensing options, which it said would be 5 cents to 6 cents per share in fiscal 2007.


Biomet in April said it hired Morgan Stanley to help it explore strategic alternatives, a week after Miller, an industry pioneer who led the company for nearly 30 years, abruptly resigned.

Earlier this week, Biomet was among several orthopedic implant makers that received subpoenas demanding documents related to the manufacture and sale of their devices as part of a U.S. Justice Department probe into possible anti-competitive practices.

The stock closed Tuesday at $31.19, down 6 percent, near its lowest level in almost three years. (Additional reporting by Herbert Lash)

[Dracull]

novo_nisto,

O que é que te fáz dizer que possa regressar aos 35$ novamente? Essa resistência já foi testada antes?

[novo_nisto]

Encontrou suporte nos 31USD, depois duma valente queda. RSI e MACD favoráveis. Parece-me que pode regressar aos 35USD em pouco tempo